Alvotech Financial Ratios
NASDAQ: ALVOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
5.78+0.11 (+1.94%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Alvotech ratio analysis
Alvotech earned a net margin of 4.8% in FY 2025, up from -47.3% a year earlier. Gross margin was 59.8% compared with a median of 42.5% over the prior 4 years. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Alvotech financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 50.00 | — | — | — | — | — |
| Price / sales | 2.47 | 7.26 | 28.53 | 23.81 | — | — |
| Gross margin | 59.8% | 62.2% | -75.9% | 22.8% | 100.0% | — |
| Operating margin | 13.3% | 14.2% | -388.1% | -417.3% | -640.3% | -206.5% |
| Net margin | 4.8% | -47.3% | -603.4% | -618.6% | -276.0% | -255.3% |
| Free cash flow margin | -19.6% | -59.3% | -377.8% | -421.9% | -676.1% | -122.8% |
| Return on assets (ROA) | 1.9% | -19.0% | -58.1% | -62.0% | -17.0% | — |
| Current ratio | 1.89 | 2.35 | 0.75 | 1.38 | 1.07 | — |
| Revenue growth | 19.7% | 435.6% | 10.1% | 125.8% | -44.8% | — |